Results 61 to 70 of about 22,997 (249)

Exposing Gender Blindness in Business Scholarship on Modern Slavery

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT The objective of this review is to analyse the treatment of gender within business scholarship on modern slavery and to propose a framework that supports more gender‐sensitive corporate responses. Modern slavery risk is an escalating concern for business, with the United Nations calling for its eradication by 2030.
Kathyayini Kathy Rao, Roger Leonard Burritt, Katherine Leanne Christ   +2 more
wiley   +1 more source

Atomic‐Scale Structurally Locked 1T/2H‐MoS2/ZnS Z‐Scheme Heterojunctions for Prolonged Charge Kinetics and Dual‐Functional Photocatalysis

ENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
Atomic‐scale structurally locked 1T/2H‐MoS2/ZnS direct Z‐scheme heterojunction enabling dual‐functional photocatalysis. The metallic 1T‐MoS2 phase serves as an electronic actuator that bridges charge transfer across the heterointerface, resulting in prolonged charge kinetics, efficient hydrogen evolution, and complete degradation of Malachite Green ...
Jeongjin Lee, Younghwon Kim, Byeong Sub Kwak, Suyeon Lee, Geunhyeong Kim, Buseong Kim, Harim Jeong, Younghwan Im, Sadanand Pandey, Hojun Moon, Misook Kang   +10 more
wiley   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Orphan products: an emerging trend in drug approvals [PDF]

Nature Reviews Drug Discovery, 2010
Timothy, Coté, Aditya, Kelkar, Kui, Xu, M Miles, Braun, M Ian, Phillips   +4 more
openaire   +2 more sources

Stereoselective Construction of Benzo‐Fused Tetrahydropyrrole Thiazines From Saccharin

European Journal of Organic Chemistry, EarlyView.
Saccharin was used as a template to construct a series of 10a‐substituted, benzo‐fused, pyrrolo thiazinone dioxides. Thereafter, diastereo‐divergent 10‐keto reduction gave either diastereomeric alcohol in a process that did not rely on the substituent at 10a's identity.
Seanán Doyle, Matthew Kiernan, Jordan Smyth, Ajay Mathew, Conor J. Crawford, Julia Bruno‐Colmenarez, Patrick J. Guiry, Aisha Khalifa, Paul Evans   +8 more
wiley   +1 more source

Perspectives on stimulating industrial research and development for neglected infectious diseases

Bulletin of the World Health Organization, 2001
This paper summarizes recent thinking on stimulating industrial research and development (R & D) for neglected infectious diseases and argues that it is critical to enlarge the value of the market for medicines and vaccines through, for example, global ...
Webber David, Kremer Michael
doaj  

Predictive Analysis for First Submission of Generic Drug Application for Orphan Drug Products Using Random Survival Forest

Clinical and Translational Science
ABSTRACT Rare diseases affect a small population of patients, resulting in low incentives for developing orphan drug products (ODPs). The United States Congress passed the Orphan Drug Act of 1983 to incentivize pharmaceutical manufacturers to develop drugs to treat rare diseases.
Robert Hopefl, Jing Wang, Abhinav Ram Mohan, Wei‐Jhe Sun, Myong‐Jin Kim, Meng Hu, Lanyan Fang   +6 more
openaire   +2 more sources

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source